AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29651598 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty screening step before GA
Number of subjects: 15
Study 29651598 — intervention group
Group type: COMPARATOR
Intervention: No geriatric assessment (GA) performed
Number of subjects: 15
Study 29651598 — intervention group
Group type: EXPERIMENTAL
Intervention: Indications for GA
Number of subjects: 15
Study 29651598 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implement GA
Number of subjects: 15
Study 29651739 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic responders (SRR positive)
Number of subjects: 839
Study 29651739 — intervention group
Group type: COMPARATOR
Intervention: Splenic non-responders (SRR negative)
Number of subjects: 839
Study 29651739 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic response
Number of subjects: 839
Study 29652233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter (CMC) for delivery of topotecan and gadolinium-DTPA (Gd-DTPA)
Number of subjects: 3
Study 29652795 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV protease inhibitor (PI)
Number of subjects: 0
Study 29652795 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 0
Study 29652795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0
Study 29653545 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral of screened-positive children to King Saud University Dental College
Number of subjects: 1010
Study 29653545 — intervention group
Group type: COMPARATOR
Intervention: Conventional referral (information letter advising parents to take their child to a dentist)
Number of subjects: 1010
Study 29653631 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA
Number of subjects: 4587
Study 29653631 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE-alone
Number of subjects: 4587
Study 29653637 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 8829
Study 29653637 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function tests (vasodilator-stimulated phosphoprotein assay, light transmittance aggregometry, VerifyNow P2Y)
Number of subjects: 8829
Study 29653640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 29653640 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 29653643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking
Number of subjects: 1601
Study 29653643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol levels >40 mg/dL for men and >50 mg/dL for women
Number of subjects: 1601
Study 29653643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress burden
Number of subjects: 1601
Study 29653643 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels <100 mg/dL
Number of subjects: 1601
Study 29653643 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 1601
Study 29653643 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of depression
Number of subjects: 1601
Study 29653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 2937
Study 29653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 2937
Study 29653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (overall)
Number of subjects: 2937
Study 29653862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 19
Study 29653862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 19
Study 29653862 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (standard diet)
Number of subjects: 19
Study 29653885 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible haematuria (VH) patients
Number of subjects: 3556
Study 29653885 — intervention group
Group type: COMPARATOR
Intervention: Nonvisible haematuria (NVH) patients
Number of subjects: 3556
Study 29653885 — intervention group
Group type: COMPARATOR
Intervention: Bladder cancer in NVH patients
Number of subjects: 3556
Study 29653885 — intervention group
Group type: EXPERIMENTAL
Intervention: VH patients <45 years
Number of subjects: 3556
Study 29653885 — intervention group
Group type: COMPARATOR
Intervention: NVH patients <60 years
Number of subjects: 3556
Study 29653920 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Gene Toolkit (Web-based intervention)
Number of subjects: 24
Study 29653920 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 24
Study 29654017 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed STIs
Number of subjects: 414
Study 29654017 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed STIs (CT, GC, Tvag)
Number of subjects: 414
Study 29654017 — intervention group
Group type: COMPARATOR
Intervention: Clinical diagnosis
Number of subjects: 414
Study 29654017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive use
Number of subjects: 414
Study 29654017 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 414
Study 29654023 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 0
Study 29654023 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-included doublet chemotherapy
Number of subjects: 0
Study 29654030 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 0
Study 29654030 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 29654045 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging intervention for 12 weeks
Number of subjects: 0
Study 29654045 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 29654049 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible family visitation model (FFVM)
Number of subjects: 50
Study 29654049 — intervention group
Group type: COMPARATOR
Intervention: Restrictive family visitation model (RFVM)
Number of subjects: 50
Study 29654125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic interventricular dyssynchrony
Number of subjects: 0
Study 29654125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic intraventricular dyssynchrony
Number of subjects: 0
Study 29654125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyssynchrony during biventricular pacing
Number of subjects: 0
Study 29654194 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Pharmacological Profile of A
Number of subjects: 60
Study 29654202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal Cardiovascular Health (ICH) metrics in youth with normal weight
Number of subjects: 300
Study 29654202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal Cardiovascular Health (ICH) metrics in youth with overweight/obese
Number of subjects: 300
Study 29654202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal Cardiovascular Health (ICH) metrics in youth with severely obese
Number of subjects: 300
Study 29654202 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH metrics overall
Number of subjects: 300
Study 29654388 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin pre-treatment (Group 1)
Number of subjects: 41
Study 29654388 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 2)
Number of subjects: 41
Study 29654439 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV)
Number of subjects: 550
Study 29654439 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 550
Study 29654485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), 8 mg/kg, intravenous infusion every 4 weeks
Number of subjects: 41
Study 29654485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 41
Study 29654518 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intervention utilizing the EPIS framework
Number of subjects: 0
Study 29654518 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIS Wheel model
Number of subjects: 0
Study 29654533 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tumor shrinkage (eTS) defined as tumor shrinkage by ≥ 10%
Number of subjects: 1100
Study 29654533 — intervention group
Group type: COMPARATOR
Intervention: No early tumor shrinkage (eTS < 10%)
Number of subjects: 1100
Study 29654599 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 15092
Study 29654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 15092
Study 29654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant use
Number of subjects: 15092
Study 29655061 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone
Number of subjects: 6265
Study 29655061 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy ± maintenance endocrine therapy
Number of subjects: 6265
Study 29655489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochleural Alternating Acoustic Beam Therapy (CAABT) for 12 weeks
Number of subjects: 11
Study 29655489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochleural Alternating Acoustic Beam Therapy (CAABT)
Number of subjects: 11
Study 29655606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 2068
Study 29655606 — intervention group
Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Score (IPSS)
Number of subjects: 2068
Study 29655606 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB) symptom score
Number of subjects: 2068
Study 29655606 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation about urinary symptoms
Number of subjects: 2068
Study 29655654 — intervention group
Group type: EXPERIMENTAL
Intervention: HCL-32
Number of subjects: 250
Study 29655662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin anti-coagulation (INR target 1.5 to 1.9)
Number of subjects: 15
Study 29655877 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg
Number of subjects: 314
Study 29655877 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10-20 mg
Number of subjects: 314
Study 29655877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 29655877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5-10 mg
Number of subjects: 314
Study 29655877 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4-8 mg
Number of subjects: 314
Study 29655877 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 314
Study 29656049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy density (LED) foods
Number of subjects: 0
Study 29656049 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density (HED) foods
Number of subjects: 0
Study 29656049 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing value and hypothetical purchase tasks
Number of subjects: 0
Study 29656708 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor plus standard care
Number of subjects: 76
Study 29656708 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 76
Study 29656714 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection without SIRS
Number of subjects: 1499
Study 29656714 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with SIRS
Number of subjects: 1499
Study 29656714 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis without shock
Number of subjects: 1499
Study 29656714 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock
Number of subjects: 1499
Study 29656714 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock (according to SEPSIS-III)
Number of subjects: 1499
Study 29656846 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ROM-Neck
Number of subjects: 50
Study 29656846 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 50
Study 29656846 — intervention group
Group type: EXPERIMENTAL
Intervention: NDI-G
Number of subjects: 50
Study 29656895 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic competence associated with chromosome complexity and 9p loss
Number of subjects: 100
Study 29656895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of metastatic dissemination
Number of subjects: 100
Study 29656895 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergence of primitive ancestral clones
Number of subjects: 100
Study 29656894 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclonal diversification and driver events in ccRCC tumors
Number of subjects: 101
Study 29656894 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolutionary subtypes of ccRCC tumors
Number of subjects: 101
Study 29656894 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity and chromosomal complexity
Number of subjects: 101
Study 29656894 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolutionary potential
Number of subjects: 101
Study 29657592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 11308
Study 29657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate Spray 0.05%
Number of subjects: 0
Study 29657830 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 0
Study 29657830 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 0
Study 29657830 — intervention group
Group type: COMPARATOR
Intervention: MTX alone or ACPA seropositive patients
Number of subjects: 0
Study 29657831 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 2.5-20 mg in combination with febuxostat (40 or 80 mg)
Number of subjects: 64
Study 29657831 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat (40 or 80 mg) alone
Number of subjects: 64
Study 29657831 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad administered with febuxostat
Number of subjects: 64
Study 29657979 — intervention group
Group type: COMPARATOR
Intervention: Ready-made spectacles (RMS)
Number of subjects: 0
Study 29657979 — intervention group
Group type: COMPARATOR
Intervention: Custom-made spectacles (CS)
Number of subjects: 0
Study 29657979 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 29658848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered intravenously every 2 weeks for 2 doses before surgery
Number of subjects: 21
Study 29658962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing 291 kcal/d for young children and 350 kcal/d for older children, administered 5 days/week for 11 weeks.
Number of subjects: 78
Study 29658962 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 78
Study 29659102 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for GAD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for PD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for SAD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for OCD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for PTSD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants across severity levels for SAD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants across severity levels for OCD
Number of subjects: 10379
Study 29659102 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants across severity levels for PTSD
Number of subjects: 10379
Study 29659205 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release for 12 weeks
Number of subjects: 468
Study 29659330 — intervention group
Group type: EXPERIMENTAL
Intervention: DD4A chemotherapy (vincristine/dactinomycin/doxorubicin) without lung radiation therapy for patients with CR.
Number of subjects: 292
Study 29659330 — intervention group
Group type: EXPERIMENTAL
Intervention: DD4A chemotherapy plus lung radiation therapy and four cycles of cyclophosphamide/etoposide for patients with IR.
Number of subjects: 292
Study 29659330 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment strategy of AREN0533.
Number of subjects: 292
Study 29659595 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and economic intimate partner violence
Number of subjects: 0
Study 29659784 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 243
Study 29659784 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical-imaging score (LAGO)
Number of subjects: 243
Study 29659847 — intervention group
Group type: EXPERIMENTAL
Intervention: OvFs
Number of subjects: 56
Study 29659847 — intervention group
Group type: COMPARATOR
Intervention: LUFs
Number of subjects: 56
Study 29659889 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (ECP) with higher anti-EBOV antibody levels
Number of subjects: 100
Study 29659889 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (ECP) with lower anti-EBOV antibody levels
Number of subjects: 100
Study 29659889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 29659958 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartIntake application
Number of subjects: 23
Study 29659958 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartIntake application (own phones)
Number of subjects: 23
Study 29659958 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartIntake application (snacks)
Number of subjects: 23
Study 29659958 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartIntake application (excluding erroneous days)
Number of subjects: 23
Study 29659964 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal salt iodization (USI) with salt iodine concentration at ∼25 mg/kg
Number of subjects: 5860
Study 29659964 — intervention group
Group type: EXPERIMENTAL
Intervention: Household salt samples in Linfen, Tuguegarao, and Zagreb
Number of subjects: 5860
Study 29659964 — intervention group
Group type: EXPERIMENTAL
Intervention: Median urinary iodine concentration (UIC)
Number of subjects: 5860
Study 29660005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg/day
Number of subjects: 108
Study 29660005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 140 mg/day
Number of subjects: 108
Study 29660005 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (Cabozantinib monotherapy)
Number of subjects: 108
Study 29660005 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumor volume
Number of subjects: 108
Study 29660005 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric response
Number of subjects: 108
Study 29660322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraductal radiofrequency ablation (ID-RFA)
Number of subjects: 20
Study 29660596 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of diagnosis as an independent predictor of overall survival (OS)
Number of subjects: 16702
Study 29660596 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in HR+/HER2- subcohort
Number of subjects: 16702
Study 29660596 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in HER2+ subcohort
Number of subjects: 16702
Study 29660596 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in HR-/HER2- subcohort
Number of subjects: 16702
Study 29660596 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in the whole cohort
Number of subjects: 16702
Study 29661197 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon-TB Gold In-Tube Test (QGIT)
Number of subjects: 56
Study 29661197 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin Screening Test (TST)
Number of subjects: 56
Study 29661249 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate STI prevention intervention developed through qualitative inquiry and community engagement.
Number of subjects: 706
Study 29661249 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention).
Number of subjects: 706
Study 29661414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 29661414 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance controlled by urology departments
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of prostate-specific antigen density (PSAd)
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of multiparametric magnetic resonance imaging (mpMRI)
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience level of radiology colleagues in mpMRI
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmation biopsy pathway
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment upon disease progression to Gleason 7 (3+4)
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent and quality-of-life questionnaires
Number of subjects: 33
Study 29661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus on follow-up protocols and active treatment criteria
Number of subjects: 33
Study 29661560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition assessment using Bayley Scales of Infant Development, Third edition
Number of subjects: 19
Study 29661560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive behavior assessment using Vineland Adaptive Behavior Scales, Second Edition
Number of subjects: 19
Study 29661560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical gray matter volume (GMV) assessment
Number of subjects: 19
Study 29661560 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine glycosaminoglycan (GAG) measurements
Number of subjects: 19